Morgan Stanley Capital Partners Recapitalizes Ovation Fertility from WindRose Health Investors
June 17, 2019
Investment funds managed by Morgan Stanley Capital Partners (MSCP) completed a recapitalization of Ovation Fertility, a Los Angeles–headquartered provider of IVF laboratories, genetic testing and embryo/egg storage. WindRose Health Investors, the prior majority sponsor, exited in the transaction while Ovation's management and physician shareholders retained roles to support continued organic and acquisitive growth.
- Targets
- Ovation Fertility
- Sellers
- WindRose Health Investors
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Recapitalization
Explore More
Related Acquisitions
-
StepStone Leads US Fertility Recapitalization
September 14, 2026
Healthcare Services
US Fertility completed a recapitalization through a new continuation vehicle, with StepStone Group acting as sole lead investor alongside other existing and new investors. The transaction provides additional long-term capital to support the fertility platform’s growth, clinical innovation, and expansion of access to reproductive care.
-
US Fertility Acquires Ovation Fertility from Morgan Stanley Capital Partners
April 3, 2023
Healthcare Services
US Fertility, the physician-led fertility practice management platform backed by Amulet Capital Partners, has acquired Ovation Fertility from investment funds managed by Morgan Stanley Capital Partners. The deal combines Ovation’s IVF laboratories and ancillary services with US Fertility’s physician network to create a national fertility platform aimed at expanding access, sharing best practices, and improving patient outcomes; financial terms were not disclosed.
-
WindRose Health Investors Recapitalizes RevHealth
July 27, 2022
Healthcare Services
WindRose Health Investors completed a recapitalization of RevHealth, a Morristown, New Jersey-based omnichannel healthcare communications agency. The investment will provide capital to support RevHealth's growth and expansion of services; founders Bruce Epstein, Bruce Medd, and Brian Wheeler will continue to lead the company and remain significant shareholders.
-
WindRose Health Investors Recapitalizes Veristat Group Inc.
April 7, 2021
Healthcare Services
WindRose Health Investors completed an equity recapitalization of Veristat Group Inc., a global clinical research organization, with Veristat management retaining a significant minority stake. The investment will provide capital and strategic resources to support Veristat's growth and expansion across clinical development, regulatory affairs, biostatistics, data management and pharmacovigilance; terms were not disclosed.
-
WindRose Health Investors Recapitalizes Lykan Bioscience Holdings
June 4, 2019
Biotechnology
WindRose Health Investors completed an equity recapitalization of Lykan Bioscience Holdings, LLC, a Hopkinton, Massachusetts-based contract manufacturing services organization focused on cell and gene therapy production and logistics. The investment provides capital to support growth and the build-out of a 60,000+ square foot cGMP facility to expand manufacturing capacity; terms were not disclosed.
-
WindRose Health Investors Recapitalizes Healthmap Solutions
May 21, 2019
Healthcare Services
WindRose Health Investors completed an $85 million equity recapitalization of Healthmap Solutions to provide growth capital and support the company's expansion into new markets. Healthmap, a specialty population health management firm focused on kidney disease, will continue to be led by CEO Joe Vattamattam and COO & Founder Andrew Wall.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.